Patient Characteristics (n = 324)
| Variable | Data |
|---|---|
| Sex | |
| Male | 168 (52%) |
| Female | 156 (48%) |
| Median age at 68Ga-FAPI scan (y) | 59 (16) |
| Tumor entity | |
| Sarcoma | 131 (40%) |
| Pancreas | 67 (21%) |
| Brain | 22 (7%) |
| Lung | 14 (4%) |
| Pleura | 12 (4%) |
| Cholangiocellular | 11 (3%) |
| Colorectal | 11 (3%) |
| Prostate | 11 (3%) |
| Head and neck | 9 (3%) |
| Bladder | 8 (3%) |
| Lymphoma | 7 (2%) |
| Myeloma | 6 (2%) |
| Ovarian | 4 (1%) |
| Breast | 3 (1%) |
| Duodenum | 2 (1%) |
| Other* | 6 (2%) |
| Tumor staging with 68Ga-FAPI scan† | |
| No evidence of disease | 19 (8%) |
| Stage I | 26 (10%) |
| Stage II | 29 (12%) |
| Stage III | 25 (10%) |
| Stage IV | 149 (60%) |
| Scanning purposes | |
| Staging at initial diagnosis | 88 (27%) |
| Restaging after therapy | 235 (73%) |
| Prior therapy received | |
| None | 88 (27%) |
| Surgery | 176 (55%) |
| Chemotherapy | 176 (55%) |
| Radiation therapy | 83 (26%) |
| Immune therapy | 27 (8%) |
| Hormone therapy | 9 (3%) |
| Radionuclide therapy | 3 (1%) |
| Median uptake time (min) | |
| 68Ga-FAPI | 14 (24) |
| 18F-FDG | 67 (23) |
| Median time between 68Ga-FAPI and 18F-FDG (d) | 0 (2) |
↵* Tumors of cervix (n = 1), liver (n = 1), skin (n = 1), thyroid (n = 1), and stomach (n = 1) and myoepithelial carcinoma of knee (n = 1).
↵† Among 7 most common tumor entities (n = 248), excluding brain tumors as well as 9 sarcoma patients (not stageable according to AJCC-8).
Qualitative data are number and percentage; continuous data are median and interquartile range.